ArticleOncogene1999
Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2.
Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development.Leukemia · 2023Article
- A proposal for clinical genetics (genetics in medicine) education for medical technologists and other health professionals in Japan.Frontiers in public health · 2014Review
- A role for RUNX1 in hematopoiesis and myeloid leukemia.International journal of hematology · 2013Review
- Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity.Leukemia · 2008Article
- The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.Blood · 2007Article
- A distinct epigenetic signature at targets of a leukemia protein.BMC genomics · 2007Article
- Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation.Oncogene · 2005Article
- Article
- Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.Oncogene · 2004Article
- Core-binding factors in hematopoiesis and immune function.Oncogene · 2004Review
- The 8;21 translocation in leukemogenesis.Oncogene · 2004Review
- Article
- Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Review
- Common themes in the pathogenesis of acute myeloid leukemia.Oncogene · 2001Review
- Review
- Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation.Molecular and cellular biology · 2001Article
- BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.The Journal of experimental medicine · 2001Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chimeric gene, AML1/ETO (MTG8), generated in t(8;21) acute myeloid leukemia enhances the expression of Bcl-2. To evaluate whether this enhancement is the primary role of AML1/ETO in leukemogenesis, effects of over-expression of Bcl-2 in the murine myeloid precursor cell line, 32Dcl3, were examined. When 32Dcl3 cells expressing exogenous Bcl-2 were induced to differentiate, the onset of morphological differentiation was delayed. However, even the cells expressing very high levels of exogenous Bcl-2 eventually underwent differentiation without a significant decrease in the synthesis of Bcl-2. On the contrary, 32Dcl3 cells stably expressing AML1/ETO were completely resistant to differentiation and continued to grow in the presence of G-CSF. These results are consistent with the interpretation that stimulation of Bcl-2 expression is not the primary target of AML1/ETO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.